Cytokinetics, Incorporated CYTK
53.17 USD -2.96 (-5.27%)
Regular-session close
52.61 -0.56 -1.05%
After hours · Nov 16, 5:27 PM ET
52.68 Day range 55.62
53.17 52-week range 87.26
- YTD
- -16.32%
- 1 year
- -19.97%
Benzinga news
benzinga.com Cytokinetics Presents New Aficamten Data From ACACIA-HCM And FOREST-HCM At HCMS Scientific Sessions 2026 New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for AficamtenSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK)…
benzinga.com Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105 Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.
benzinga.com Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100 Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $103 to $100.
benzinga.com Cytokinetics Q3 2026 Earnings Call Transcript Cytokinetics (NASDAQ:CYTK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Cytokinetics Q3 EPS $(1.37) Beats $(1.44) Estimate, Sales $47.557M Beat $41.879M Estimate Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.44) by 4.86 percent. This is a 11.04 percent increase over losses of $(1.54)…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
benzinga.com Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive…
